@article{3076835,
    title = "Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus",
    author = "Atkinson, V. and Robert, C. and Grob, J.J. and Gogas, H. and Dutriaux, C. and Demidov, L. and Gupta, A. and Menzies, A.M. and Ryll, B. and Miranda, F. and Banerjee, H. and Lau, M. and Del Vecchio, M.",
    journal = "EUROPEAN JOURNAL OF CANCER",
    year = "2022",
    volume = "163",
    pages = "79-87",
    publisher = "Elsevier Ireland Ltd",
    doi = "10.1016/j.ejca.2021.12.015",
    keywords = "B Raf kinase;  creatine kinase;  dabrafenib;  trametinib, adult;  adverse outcome;  arthralgia;  Article;  asthenia;  cancer adjuvant therapy;  cause of death;  chill;  creatine kinase blood level;  diarrhea;  disease exacerbation;  drug withdrawal;  fatigue;  female;  fever;  headache;  hospitalization;  human;  major clinical study;  male;  melanoma;  middle aged;  multicenter study;  nausea;  open study;  phase 3 clinical trial;  primary tumor;  rash;  recurrence free survival;  side effect;  treatment duration",
    abstract = "Background: COMBI-AD demonstrated long-term benefit of adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600E/K–mutant melanoma; however, 9% of patients permanently discontinued therapy due to pyrexia. COMBI-APlus evaluated whether an adapted pyrexia management algorithm reduces high-grade pyrexia and pyrexia-related adverse outcomes. Methods: COMBI-APlus is an open-label, phase IIIb trial evaluating an adapted pyrexia management algorithm in patients with high-risk resected stage III BRAF V600E/K–mutant melanoma treated with up to 12 months of adjuvant dabrafenib plus trametinib. Both drugs were interrupted for pyrexia (temperature ≥38°C) or the occurrence of pyrexia syndrome for suspected recurrent pyrexia. Treatment was restarted at the same dose once patients were symptom free for ≥24 h. The primary endpoint was the composite rate of grade 3/4 pyrexia, hospitalisation due to pyrexia, or permanent discontinuation due to pyrexia versus historical COMBI-AD control (20.0%; 95% confidence interval [CI], 16.3%–24.1%). Results: At data cutoff (5 October 2020), COMBI-APlus met its primary endpoint of significant improvement in the composite rate of pyrexia (8.0% [95% CI, 5.9%–10.6%]), with rates of 3.8% for grade 3/4 pyrexia, 4.3% for hospitalisation due to pyrexia, and 2.4% for discontinuation due to pyrexia. Estimated 12-month relapse-free survival was 91.8% (95% CI, 89.0%–93.9%). The most common adverse events were consistent with those in COMBI-AD, and 14.7% of patients permanently discontinued treatment due to adverse events. Conclusions: The adapted pyrexia management algorithm appears to reduce the incidence of severe pyrexia outcomes, enables patients to manage pyrexia at home, and helps patients remain on treatment. Clinical trial registration: NCT03551626. © 2021 The Authors"
}